Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy

Cancers

Volumn 3, Issue 2, 2011, Pages 2176-2194

  Spolverato, Gaya ^a   Pucciarelli, Salvatore ^a   Bertorelle, Roberta ^b   de Rossi, Anita ^a,b   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Biomarkers; Neoadjuvant therapy; Rectal cancer

Indexed keywords

CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CELL FREE DNA; CETUXIMAB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KI 67 ANTIGEN; MESSENGER RNA; MICRORNA; MOLECULAR MARKER; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; THYMIDYLATE SYNTHASE; UFT; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER STAGING; CHEMORADIOTHERAPY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HUMAN; MEDLINE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PATIENT SELECTION; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIATION EXPOSURE; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 79959694804     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3022176     Document Type: Review

References (98)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.D.; Parkin, D. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr/ (accessed 10 January 2011).
3. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
4. Winder, T.; Lenz, H.J. Molecular predictive and prognostic markers in colon cancer. Cancer Treat. Rev. 2010, 36, 550-556.
5. Vogelstein, B.; Fearon, E.R.; Hamilton, S.R.; Kern, S.E.; Preisinger, A.C.; Leppert, M.; Nakamura, Y.; White, R.; Smits, A.M.; Bos, J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319, 525-532.
6. Noffsinger, A.E. Serrated polyps and colorectal cancer: New pathway to malignancy. Annu. Rev. Pathol. 2009, 4, 343-364.
7. Boyle, P.; Leon, M.E. Epidemiology of colorectal cancer. Br. Med. Bull. 2002, 64,1-25.
8. National Comprehensive Cancer Network Home Page. http://www.nccn.org/ (accessed 10 January 2011).
9. Bosset, J.F. Distal rectal cancer: Sphincter-sparing is also a challenge for the radiation oncologist. Radiother. Oncol. 2006, 80, 1-3.
10. Sauer, R.; Becker, H.; Hohenberger, W. Preoperative versus postoperative chemoradio therapy for rectal cancer. N. Engl. J. Med. 2004, 351, 1731-1740.
11. Gérard, J.P.; Conroy, T.; Bonnetain, F.; Bouché, O.; Chapet, O.; Closon-Dejardin, M.T.; Untereiner, M.; Leduc, B.; Francois, E.; Maurel, J.; et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J. Clin. Oncol. 2006, 24, 4620-4625
12. Pucciarelli, S.; Del Bianco, P.; Efficace, F.; Serpentini, S.; Capirci, C.; De Paoli, A.; Amato, A.; Cuicchi, D.; Nitti, D. Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: A multicenter prospective observational study. Ann. Surg. 2011, 253, 71-77.
13. Minsky, B.D.; Cohen, A.M.; Kemeny, N.; Enker, W.E.; Kelsen, D.P.; Reichman, B.; Saltz, L.; Sigurdson, E.R.; Frankel, J. Combined modality therapy of rectal cancer: Decreased acute toxicity with the preoperative approach. J. Clin. Oncol. 1992, 10, 1218-1224.
14. Mohiuddin, M.; Hayne, M.; Regine, W.F.; Hanna, N.; Hagihara, P.F.; McGrath, P.; Marks, G.M. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 1075-1080.
15. Maas, M.; Nelemans, P.J.; Valentini, V.; Das, P.; Rödel, C.; Kuo, L.J.; Calvo, F.A.; García-Aguilar, J.; Glynne-Jones, R.; Haustermans, K.; et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol. 2010, 11, 835-44.
16. Habr-Gama, A.; Perez, R.O.; Nadalin, W.; Sabbaga, J.; Ribeiro, U., Jr.; Silva e Sousa, A.H., Jr.; Campos, F.G.; Kiss, D.R.; Gama-Rodrigues, J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long-term results. Ann. Surg. 2004, 240, 711-717.
17. Smith, F.M.; Waldron, D.; Winter, D.C. Rectum-conserving surgery in the era of chemoradiotherapy. Br. J. Surg. 2010, 97, 1752-1764.
18. Mandard, A.M.; Dalibard, F.; Mandard, J.C.; Marnay, J.; Henry-Amar, M.; Petiot, J.F.; Roussel, A.; Jacob, J.H.; Segol, P.; Samama, G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994, 73, 2680-2686.
19. Dworak, O.; Keilholz, L.; Hoffmann, A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis. 2000, 43, 1075-1083.
20. Beddy, D.; Hyland, J.M., Winter, D.C.; Lim, C.; White, A.; Moriarty, M.; Armstrong, J.; Fennelly, D.; Gibbons, D.; Sheahan, K. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann. Surg. Oncol. 2008, 15, 3471-3477.
21. American Joint Committee on Cancer Home Page. http://www.cancerstaging.org/ (accessed 10 January 2011).
22. Kim, M.J.; Lim, J.S.; Oh, Y.T.; Kim, J.H.; Chung, J.J.; Joo, S.H.; Kim, N.K.; Lee, K.Y.; Kim, W.H.; Kim, K.W. Preoperative MRI of rectal cancer with and without rectal water filling: An intraindividual comparison. Am. J. Roentgenol. 2004, 182, 1469-1476.
23. Chen, C.C.; Lee, R.C.; Lin, J.K.; Wang, L.W.; Yang, S.H. How accurate is magnetic resonance in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis. Colon Rectum 2005, 48, 722-728.
24. Maretto, I.; Pomerri, F.; Pucciarelli, S.; Mescoli, C.; Belluco, E.; Burzi, S.; Rugge, R.; Muzzio, P.C.; Nitti, D. The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann. Surg. Oncol. 2007, 14, 455-461.
25. Yoshida, K.; Miki, Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci. 2010, 101, 831-835.
26. Pasche, B.; Mulcahy, M.; Benson, A.B., 3rd. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Pract. Res. Clin. Gastroenterol. 2002, 16, 331-345.
27. Kuerbitz, S.J.; Plunkett, B.S.; Walsh, W.V.; Kastan, M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 1992, 89, 7491-7495.
28. Lowe, S.W.; Bodis, S.; McClatchey, A.; Remington, L.; Ruley, H.E.; Fisher, D.E.; Housman, D.E.; Jacks, T. P53 status and the efficacy of cancer therapy in vivo. Science 1994, 266, 807-810.
29. McIlwrath, A.J.; Vasey, P.A.; Ross, G.M.; Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994, 54, 3718-3722.
30. Terzi, C.; Canda, A.E.; Sagol, O.; Atila, K.; Sonmez, D.; Fuzun, M.; Gorken, I.B.; Oztop, I.; Obuz, F. Survivin, P53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int. J. Colorectal Dis. 2008, 23, 37-45.
31. Sturm, I.; Rau, B.; Schlag, P.M.; Wust, P.; Hildebrandt, B.; Riess, H.; Hauptmann, S.; Dörken, B.; Daniel, P.T. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer 2006, 6, 124.
32. Chang, H.J.; Jung, K.H.; Kim, D.Y.; Jeong, S.Y.; Choi, H.S.; Kim, Y.H.; Sohn, D.K.; Yoo, B.C.; Lim, S.B.; Kim, D.H.; et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum. Pathol. 2005, 36, 364-371.
33. Bertolini, F.; Bengala, C.; Losi, L.; Pagano, M.; Iachetta, F.; Dealis, C.; Jovic, G.; Depenni, R.; Zironi, S.; Falchi, A.M.; et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68, 1455-1461.
34. Negri, F.V.; Campanini, N.; Camisa, R.; Pucci, F.; Bui, S.; Ceccon, G.; Martinelli, R.; Fumagalli, M.; Losardo, P.L.; Crafa, P.; et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br. J. Cancer 2008, 98, 143-147.
35. Moral, M.; Fdez-Aceñero, M.J.; Cuberes, R.; Suárez, A. Factors influencing prognosis after neo-adjuvant chemoradiation therapy for rectal carcinoma. Acta Chir. Belg. 2009, 109, 345-51.
36. Jakob, C.; Liersch, T.; Meyer, W.; Becker, H.; Baretton, G.B.; Aust, D.E. Predictive value of Ki67 and p53 in locally advanced rectal cancer: Correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J. Gastroenterol. 2008, 14, 1060-1066.
37. Huerta, S.; Hrom, J.; Gao, X.; Saha, D.; Anthony, T.; Reinhart, H.; Kapur, P. Tissue microarray constructs to predict a response to chemoradiation in rectal cancer. Dig. Liver Dis. 2010, 42, 679-684.
38. Kudrimoti, M.; Lee, E.Y.; Kang, Y.; Ahmed, M.; Mohiuddin, M. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers. J. Ky Med. Assoc. 2007, 105, 18-22.
39. Lin, L.C.; Lee, H.H.; Hwang, W.S.; Li, C.F.; Huang, C.T.; Que, J.; Lin, K.L.; Lin, F.C.; Lu, C.L. P53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg. Oncol. 2006, 15, 211-216.
40. Karlberg, M.; Ohrling, K.; Edler, D.; Hallström, M.; Ullén, H.; Ragnhammar, P. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res. 2010, 30, 645-651.
41. Kuremsky, J.G.; Tepper, J.E.; McLeod, H.L. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74, 673-688.
42. Carlomagno, C.; Pepe, S.; D'Armiento, F.P.; D'Armiento, M.; Cannella, L.; De Stefano, A.; Crispo, A.; Giordano, M.; De Placido, S. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Oncology 2010, 78, 369-375.
43. Kikuchi, M.; Mikami, T.; Sato, T.; Tokuyama, W.; Araki, K.; Watanabe, M.; Saigenji, K.; Okayasu, I. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: Proposal of a logistic model for prediction. Br. J. Cancer 2009, 101, 116-123.
44. Kawakami, K.; Watanabe, G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 2003, 63, 6004-6007.
45. Mandola, M.V.; Stoehlmacher, J.; Muller-Weeks, S.; Cesarone, G.; Yu, M.C.; Lenz, H.J.; Ladner, R.D. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003, 63, 2898-2904.
46. Mandola, M.V.; Stoehlmacher, J.; Zhang, W.; Groshen, S.; Yu, M.C.; Iqbal, S.; Lenz, H.J.; Ladner, RD. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004, 14, 319-327.
47. Stoehlmacher, J.; Goekkurt, E.; Mogck, U. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett. 2008, 272, 221-225.
48. Spindler, K.L.; Nielsen, J.N.; Lindebjerg, J.; Brandslund, I.; Jakobsen, A. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66, 500-504.
49. Spindler, K.L.; Nielsen, J.N.; Lindebjerg, J.; Jakobsen, A. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis. Colon Rectum 2007, 50, 1363-1369.
50. Hur, H.; Kang, J.; Kim, N.K.; Min, B.S.; Lee, K.Y.; Shin, S.J.; Keum, K.C.; Choi, J.; Kim, H.; Choi, S.H.; et al. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, doi:10.1016/j.ijrobp.2010.06.049.
51. Páez, D.; Paré, L.; Altés, A.; Sancho-Poch, F.J.; Petriz, L.; Garriga, J.; Monill, J.M.; Salazar, J.; del Rio, E.; Barnadas, A.; et al. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. J. Cancer Res. Clin. Oncol. 2010, 136,1681-1689.
52. Terrazzino, S.; Agostini, M.; Pucciarelli, S.; Pasetto, L.M.; Friso, M.L.; Ambrosi, A.; Lisi, V.; Leon, A.; Lise, M.; Nitti, D. A haplotype of the methylenete trahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet. Genomics 2006, 16, 817-824.
53. Yeh, K.H.; Cheng, A.L.; Wan, J.P.; Lin, C.S.; Liu, C.C. Down-regulation of thymidylate synthase expression and its staedy-state mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs 2004, 15, 371-376.
54. Kim, J.S.; Kim, J.M.; Li, S.; Yoon, W.H.; Song, K.S.; Kim, K.H.; Yeo, S.G.; Nam, J.S.; Cho, M.J. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66, 195-200.
55. Giralt, J.; de las Heras, M.; Cerezo, L.; Eraso, A.; Hermosilla, E.; Velez, D.; Lujan, J.; Espin, E.; Rosello, J.; Majó, J.; et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: A multicenter, retrospective analysis. Radiother. Oncol. 2005, 74, 101-108.
56. Toiyama, Y.; Inoue, Y.; Saigusa, S.; Okugawa, Y.; Yokoe, T.; Tanaka, K.; Miki, C.; Kusunoki, M. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clin. Oncol. 2010, 22, 272-280.
57. Debucquoy, A.; Haustermans, K.; Daemen, A.; Aydin, S.; Libbrecht, L.; Gevaert, O.; De Moor, B.; Tejpar, S.; McBride, W.H.; Penninckx, F.; et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J. Clin. Oncol. 2009, 27, 2751-2757.
58. Bengala, C.; Bettelli, S.; Bertolini, F.; Salvi, S.; Chiara, S.; Sonaglio, C.; Losi, L.; Bigiani, N.; Sartori, G.; Dealis, C.; et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann. Oncol. 2009, 20, 469-474.
59. Bengala, C.; Bettelli, S.; Bertolini, F; Sartori, G.; Fontana, A; Malavasi, N.; Depenni, R.; Zironi, S.; Del Giovane, C.; Luppi, G.; et al. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br. J. Cancer 2010, 103, 1019-1024.
60. Horisberger, K.; Treschl, A.; Mai, S.; Barreto-Miranda, M.; Kienle, P.; Ströbel, P.; Erben, P.; Woernle, C.; Dinter, D.; Kähler, G.; et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: Results of a phase II MARGIT trial. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74, 1487-1493.
61. Kim, S.Y.; Kim, S.Y.; Hong, Y.S.; Kim, D.Y.; Kim, T.W.; Kim, J.H.; Im, S.A.; Lee, K.S.; Yun, T.; Jeong, S.Y.; et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: A multicenter phase II study. Int. J. Radiat. Oncol. Biol. Phys. 2010, doi:10.1016/j.ijrobp.2010.06.035.
62. Erben, P.; Ströbel, P.; Horisberger, K.; Popa, J.; Bohn, B.; Hanfstein, B.; Kähler, G.; Kienle, P.; Post, S.; Wenz, F.; et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, doi:10.1016/j.ijrobp.2010.06.043.
63. Debucquoy, A.; Machiels, J.P.; McBride, W.H.; Haustermans, K.C. Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. Clin. Cancer Res. 2010, 16, 2709-2714.
64. Scholzen, T.; Gerdes, J. The Ki-67 protein: From the known and the unknown. J. Cell. Physiol. 2000, 182, 311-322.
65. Debucquoy, A.; Goethals, L.; Geboes, K.; Roels, S.; McBride, W.H.; Haustermans, K. Molecular responses of rectal cancer to preoperative chemoradiation. Radiother. Oncol. 2006, 80, 172-177.
66. Debucquoy, A.; Libbrecht, L.; Roobrouck, V.; Goethals, L.; McBride, W.H.; Haustermans, K. Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: Prognostic value and effects of preoperative radio (chemo) therapy. Eur. J. Cancer 2008, 44, 791-797.
67. Smith, F.M.; Reynolds, J.V.; Kay, E.W.; Crotty, P.; Murphy, J.O.; Hollywood, D.; Gaffney, E.F.; Stephens, R.B.; Kennedy, M.J. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64, 466-472.
68. Harper, J.W.; Adami, G.R.; Wei, N.; Keyomarsi, K.; Elledge, S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75, 805-816.
69. El-Deiry, W.S.; Harper, J.W.; O'Connor, P.M.; Velculescu, V.E.; Canman, C.E.; Jackman, J.; Pietenpol, J.A.; Burrell, M.; Hill, D.E.; Wang, Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54, 1169-1174.
70. Roninson, I.B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002, 179,1-14.
71. Yamaguchi, H.; Bhalla, K.; Wang, H.G. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res. 2003, 63, 1483-1489.
72. Wagener, C.; Bargou, R.C.; Daniel, P.T.; Bommert, K.; Mapara, M.Y.; Royer, H.D.; Dörken, B. Induction of the deathpromoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int. J. Cancer 1996, 67, 138-141.
73. Min, B.S.; Choi, Y.J.; Pyo, H.R.; Kim, H.; Seong, J.; Chung, H.C.; Rha, S.Y.; Kim, N.K. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer. Arch. Surg. 2008, 143, 1091-1097.
74. Rajewsky, N. MicroRNA target predictions in animals. Nat. Genet. 2006, 38, S8-S13.
75. Svoboda, M.; Izakovicova Holla, L.; Sefr, R.; Vrtkova, I.; Kocakova, I.; Tichy, B.; Dvorak, J. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int. J. Oncol. 2008, 33, 541-547.
76. Agostini, M.; Pucciarelli, S.; Calore, F.; Bedin, C.; Enzo, M.; Nitti, D. MiRNAs in colon and rectal cancer: A consensus for their true clinical value. Clin. Chim. Acta 2010, 411, 1181-1186.
77. Ghadimi, B.M.; Grade, M.; Difilippantonio, M.J.; Varma, S.; Simon, R.; Montagna, C.; Füzesi, L.; Langer, C.; Becker, H.; Liersch, T.; Ried, T. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J. Clin. Oncol. 2005, 23, 826-838.
78. Rimkus, C.; Friederichs, J.; Boulesteix A.L.; Theisen, J.; Mages, J.; Becker, K.; Nekarda, H.; Rosenberg, R.; Janssen, K.P.; Siewert, J.R. Microarraybased prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin. Gastroenterol. Hepatol. 2008, 6, 53-61.
79. Park, Y.A.; Sohn, S.K.; Seong, J.; Baik, S.H.; Lee, K.Y.; Kim, N.K.; Cho, C.W. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J. Surg. Oncol. 2006, 93, 145-150.
80. Das, P.; Skibber, J.M.; Rodriguez-Bigas, M.A.; Feig, B.W.; Chang, G.J.; Wolff, R.A.; Eng, C.; Krishnan, S.; Janjan, N.A.; Crane, CH. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007, 109, 1750-1755.
81. Moureau-Zabotto, L.; Farnault, B.; de Chaisemartin, C.; Esterni, B.; Lelong, B.; Viret, F.; Giovannini, M.; Monges, G.; Delpero, J.R.; Bories, E.; et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, doi:10.1016/j.ijrobp.2010.02.025.
82. Perez, R.O.; São Julião, G.P.; Habr-Gama, A.; Kiss, D.; Proscurshim, I.; Campos, F.G.; Gama-Rodrigues, J.J.; Cecconello, I. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis. Colon Rectum 2009, 52, 1137-1143.
83. Blackburn, E.H.; Greider, C.W.; Szostak, J.W. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat. Med. 2006, 12, 1133-1138.
84. Dolcetti R.; De Rossi, A. Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: Pathogenetic and clinical implications. Med. Res. Rev. 2010, doi: 10.1002/med.20211.
85. Terrin, L.; Rampazzo, E.; Pucciarelli, S.; Agostini, M.; Bertorelle, R.; Esposito, G.; Del Bianco, P.; Nitti, D.; De Rossi, A. Relationship between tumor and plasma levels of hTERT mRNA in patients with with colorectal cancer: Implications for monitoring of neoplastic disease. Clin. Cancer Res. 2008, 14, 7444-7451.
86. Pucciarelli, S.; Rampazzo, E.; Briarava, M.; Serra, L.; Bedin, C.; Lonardi, S.; Mescoli, C.; Digito, M.; De Rossi, A.; Nitti, D. Plasma levels of total RNA and hTERT mRNA as biomarkers of response in rectal cancer patients receiving preoperative chemoradiotherapy. J. Clin. Oncol. 2010, 28, Abstract 3648.
87. Agostini, M.; Pucciarelli, S.; Enzo, M.V.; Del Bianco, P.; Briarava, M.; Bedin, C.; Maretto, I.; Friso, M.L.; Lonardi, S.; Mescoli, C.; et al. Circulating cell-free DNA: A promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann. Surg. Oncol. 2011, doi: 10.1245/s10434-011-1638-y.
88. Tulchinsky, H.; Shmueli, E.; Figer, A; Klausner, J.M.; Rabau, M. An interval 7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann. Surg. Oncol. 2008, 24, 1181-1186.
89. Kalady, M.F.; de Campos-Lobato, L.F.; Stocchi, L.; Geisler, D.P.; Dietz, D.; Lavery, I.C.; Fazio, V.W. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann. Surg. 2009, 250, 582-589.
90. de Campos-Lobato, L.F.; Geisler, D.; da Luz Moreira, A.; Stocchi, L.; Dietz, D.; Kalady, M.F. Neoadjuvant therapy for rectal cancer: The impact of longer interval between chemoradiation and surgery. J. Gastrointest. Surg. 2011, 15, 444-450.
91. Guillem, J.G.; Díaz-González, J.A.; Minsky, B.D.; Valentini, V.; Jeong, S.Y.; Rodriguez-Bigas, M.A.; Coco, C.; Leon, R.; Hernandez-Lizoain, J.L.; Aristu, J.J.; et al. CT3N0 rectal cancer: Potential overtreatment with preoperative chemoradiotherapy is warranted. J. Clin. Oncol. 2008, 26, 368-373.
92. Pomerri, F.; Pucciarelli, S.; Maretto, I.; Zandonà, M.; Del Bianco, P.; Amadio, L.; Rugge, M.; Nitti, D.; Muzzio, P.C. Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. Surgery 2011, 149, 56-64.
93. Rödel, C.; Martus, P.; Papadoupolos, T.; Füzesi, L.; Klimpfinger, M.; Fietkau, R.; Liersch, T.; Hohenberger, W.; Raab, R.; Sauer, R.; et al. Prognostic significante of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol. 2005, 23, 8688-8696.
94. Buchholz, T.A.; Stivers, D.N.; Stec, J.; Ayers, M.; Clark, E.; Bolt, A.; Sahin, A.A.; Symmans, W.F.; Hess, K.R.; Kuerer, H.M.; et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002, 8, 461-468.
95. Smith, F.M.; Reynolds, J.V.; Miller, N.; Stephens, R.B.; Kennedy, M.J. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur. J. Surg. Oncol. 2006, 32, 55-64.
96. de Geus-Oei, L.F.; Vriens, D.; van Laarhoven, H.W.; van der Graaf, W.T.; Oyen, W.J. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review. J. Nucl. Med. 2009, 50, 43S-54S.
97. Kim, S.H.; Lee, J.M.; Hong, S.H.; Kim, G.H.; Lee, J.Y.; Han, J.K.; Choi, B.I. Locally advanced rectal cancer: Added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009, 253, 116-125.
98. Kim, D.J.; Kim, J.H.; Lim J.S.; Yu J.S.; Chung J.J.; Kim, M.J.; Kim, K.W. Restaging of rectal cancer with MR imaging after concurrent chemotherapy and radiation therapy. Radiographics 2010, 30, 503-516.